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ABSTRACT
IBS is one of the most common types of functional bowel
disorder. Increasing attention has been paid to the
causative role of food in IBS. Food ingestion precipitates or
exacerbates symptoms, such as abdominal pain and
bloating in patients with IBS through different
hypothesised mechanisms including immune and mast cell
activation, mechanoreceptor stimulation and
chemosensory activation. Wheat is regarded as one of the
most relevant IBS triggers, although which component(s)
of this cereal is/are involved remain(s) unknown. Gluten,
other wheat proteins, for example, amylase-trypsin
inhibitors, and fructans (the latter belonging to
fermentable oligo-di-mono-saccharides and polyols
(FODMAPs)), have been identiﬁed as possible factors for
symptom generation/exacerbation. This uncertainty on the
true culprit(s) opened a scenario of semantic deﬁnitions
favoured by the discordant results of double-blind
placebo-controlled trials, which have generated various
terms ranging from non-coeliac gluten sensitivity to the
broader one of non-coeliac wheat or wheat protein
sensitivity or, even, FODMAP sensitivity. The role of
FODMAPs in eliciting the clinical picture of IBS goes
further since these short-chain carbohydrates are found in
many other dietary components, including vegetables and
fruits. In this review, we assessed current literature in order
to unravel whether gluten/wheat/FODMAP sensitivity
represent ‘facts’ and not ‘ﬁction’ in IBS symptoms. This
knowledge is expected to promote standardisation in
dietary strategies (gluten/wheat-free and low FODMAP) as
effective measures for the management of IBS symptoms.
INTRODUCTION
IBS can be considered the prototype of all func-
tional bowel disorders for its high prevalence
worldwide and impact on patients’ quality of
life.1 2 Patients with IBS suffer from abdominal
pain or discomfort associated with bowel habit
changes. In the absence of established biomarkers,
for which research is actively ongoing, the diagno-
sis relies upon symptom evaluation according to
the well-known Rome III criteria, which are cur-
rently the benchmark for IBS identiﬁcation.1 2
Current estimates indicate that IBS prevalence
ranges from 10% to 25% in the general population
with a typical predominance of young adult
women (3:1 F:M ratio).3–6 Usually regarded as a
harmless disorder, IBS is known to severely hamper
the patient’s quality of life at least as much as
organic disorders and is responsible for repeated
absence from work as well as suboptimal perform-
ance on the workplace with relevant social costs.
The mechanisms leading to symptom generation
in IBS remain highly debated, although growing
knowledge indicates that multiple factors are
involved. Altered brain–gut axis with gut dysmoti-
lity and hypersensitivity, immune activation, leaky
gut barrier function, changes in gut microbiome,
genetic factors, infections, as well as psychological/
psychiatric factors, can all contribute to symptom
generation.5 7 8 The interest of the scientiﬁc com-
munity for these mechanisms has somehow
obscured one of the most logical pathogenic factors
—the role of food in triggering and perpetuating
IBS symptoms. Recently, however, a number of
studies linking type of food consumption to func-
tional symptoms refuelled the interest in dietary
factors in IBS, thus opening new avenues to treat-
ment strategies.9 This review aims ﬁrst to brieﬂy
address some key mechanisms involved in
food-related symptom genesis; and second, to
address the ongoing controversy about wheat,
gluten and fermentable oligo-di-mono-saccharides
and polyols (FODMAPs) in IBS, a controversy that
is generating much debate and a growing body of
research that is slowly sorting fact from ﬁction.
MECHANISMS BY WHICH FOOD MIGHT
INDUCE SYMPTOMS
Common clinical experience indicates that food
ingestion precipitates or exacerbates symptoms,
Key messages
▸ Dietary factors are known to precipitate/
exacerbate IBS symptoms, for example,
abdominal pain, bloating and bowel habit
changes.
▸ Gluten, wheat and related proteins (eg,
amylase-trypsin inhibitors, and fermentable
oligo-di-mono-saccharides and polyols
(FODMAPs) are the most relevant IBS symptom
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▸ Double-blind placebo-controlled with cross-over
trials represent the current gold standard for
conﬁrming the dietary factor(s) involved in
functional symptom generation.
▸ Based on the different dietary factors
responsible for symptom generation, patients
can be labelled non-coeliac gluten sensitive or
more broadly non-coeliac wheat or wheat
protein sensitivity or, even, FODMAP sensitive.
▸ A better understanding of gluten/wheat/
FODMAP sensitivity can be translated into new
effective dietary strategies for the management
of patients with IBS.
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such as abdominal pain and bloating, in about 60% of patients
with IBS. The onset or worsening of symptoms can occur
rapidly after meal ingestion, namely, within 15 min in 28%, up
to 3 h in 93% of patients with IBS.10 Foods can trigger symp-
toms in IBS via several possible mechanisms, which include
immune and mast cell activation, mechanoreceptor activation
via luminal distension associated with visceral hypersensitivity
and altered motility, and chemosensory activation by bioactive
molecule activity (‘food chemicals’) (ﬁgure 1).11
Immune and mast cell activation
Low-grade inﬂammation (mainly characterised by a dense mast
cell inﬁltrate) is present in colonic mucosal biopsies of about
two-thirds of patients with IBS.12 Mast cells are known to release
a variety of mediators, including serine proteases, which evoke
neuronal hyperexcitability, a major factor for functional
symptom generation (eg, pain).13 14 Food components, particu-
larly proteins, may be pathogenically involved with this process,
either primarily or secondarily. One possible interpretation of
such mucosal changes is that food components/antigens pass
through a leaky (ie, more permeable) epithelial barrier, leading to
mast cell inﬁltration and activation, thereby leading to IBS symp-
toms.5 8 Mast cells can be activated by allergy-like mechanisms,
such as those involving food-speciﬁc immunoglobulin E (IgE).
However, tests for food allergy detection that use the systemic
immune compartment, such as skin-prick tests, have a poor sensi-
tivity and speciﬁcity.15 Thus, immune response to food in IBS
may require more sophisticated approaches to be demonstrated.
One method is to present the offending protein to the gut
immune compartment. A sort of ‘mucosal prick test’ renamed as
colonoscopic allergen provocation (COLAP) test involves
colonoscopy-guided submucosal injection to unravel food
hypersensitivity.16 Seventy-seven per cent of a population with
gut symptoms thought possibly related to food hypersensitivity
had a positive COLAP test, which was consistently negative in
the few control subjects. A more reﬁned technique (confocal
laser endomicroscopy) demonstrated that submucosal injection
of food antigens caused increased inﬁltration with intraepithelial
lymphocytes (IEL), formation of epithelial leaks/gaps and
widening of intervillous spaces in more than half of IBS, and
not in a small group of controls.17 These changes occurred
within a few minutes of food antigen injection and predicted
the clinical response to speciﬁc food withdrawal. Alternatively,
circulating basophils have been used to determine allergens in
vitro without the need to risk an allergic reaction when the
patient is challenged. Indeed, basophil activation when exposed
in vitro to dietary proteins, especially of wheat and milk origin,
correlated with clinical responsiveness to dietary restriction of
the relevant protein by one group,18 but another could ﬁnd no
speciﬁcity for basophil activation.19 Overall, these studies do
suggest that reaction to food, whether it be via allergic, other
immune or epithelial-damaging mechanisms, may play a role in
the genesis of symptoms in some patients presenting with IBS.
Conﬁrmatory studies are needed before reaching diagnostic
relevance.
Mechanoreceptor activation
Many different foods can evoke intestinal (luminal) distension,
which, in the presence of visceral hypersensitivity and abnormal
gut motility, may trigger bloating, abdominal pain and changes
in bowel habit. Dietary FODMAPs are believed to act via
luminal distension as discussed later.20–22
Figure 1 Synopsis illustrating the interplay among several dietary factors, such as gluten, wheat and fermentable oligo-di-mono-saccharides and
polyols (FODMAPs), that contribute to generate a wide array of symptoms in patients with IBS. For example, in the gut lumen, the interaction
between dietary factors (carbohydrates, lipids and proteins) and the microbiota results in gas production and/or passage of noxious macromolecules
triggering the release of mast cell mediators and the activation of the immune system. These mechanisms are at the base of mechanoreceptor and
sensory nerve pathway activation ultimately responsible for commonly reported symptoms, such as abdominal pain, bloating and distension,
especially in genetically predisposed patients. Moreover, stress or gliadomorphin evoked anxiety/depression, can directly impair intestinal barrier
function, thus favouring passage of previously mentioned noxious macromolecules. ENS, enteric nervous system; IgE, immunoglobulin E; IgG,
immunoglobulin G; IL4, interleukin-4; INF-γ, interferon-γ; TNFα, tumour necrosis factor α.
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Chemosensory activation by bioactive molecules
A wide array of foods contains potentially bioactive chemicals,
such as salicylates, amines, benzoates and glutamate, which can
elicit neurally and/or mast cell-mediated mechanisms contribut-
ing to IBS symptoms.11 23 24 However, a speciﬁc cause–effect
mechanism between bioactive chemicals and symptoms is still
far from being established. Empirical clinical experience indi-
cates an improvement of IBS symptoms as a result of reduction
of the dietary intake of bioactive chemicals. Nonetheless, clini-
cians should have a cautionary approach before advising dietary
restrictions as nutritional defects may became a serious issue for
the patient.
WHEAT SENSITIVITY
Wheat is considered one of the foods known to evoke IBS
symptoms.25 However, which component(s) of wheat is/are
actually responsible for these clinical effects still remain(s) an
unsettled issue.26 The two parts of wheat that are thought to
have a mechanistic effect comprise proteins (primarily, but not
exclusively, gluten) and carbohydrates (primarily indigestible
short-chain components, FODMAPs). Two distinct views charac-
terise the clinical debate: one line identiﬁes wheat proteins as a
precipitating/perpetuating factor leading to symptoms, while the
other believes that FODMAPs are the major trigger for IBS.
The controversy over nomenclature
If gluten is a major trigger for IBS, it expands the gluten-related
disorders by adding a new entity now referred to as non-coeliac
gluten sensitivity (NCGS).27 Indeed, coeliac disease-like abnor-
malities were reported in a subgroup of patients with IBS many
years ago.28 A recent expert group of researchers reached unani-
mous consensus attesting the existence of a syndrome triggered
by gluten ingestion.29 This syndrome recognises a wide spec-
trum of symptoms and manifestations including an IBS-like
phenotype, along with an extra-intestinal phenotype, that is,
malaise, fatigue, headache, numbness, mental confusion (‘brain
fog’), anxiety, sleep abnormalities, ﬁbromyalgia-like symptoms
and skin rash. In addition, other possible clinical features
include gastro-oesophageal reﬂux disease, aphthous stomatitis,
anaemia, depression, asthma and rhinitis. Symptoms or other
manifestations occur shortly after gluten consumption and dis-
appear or recur in a few hours (or days) after gluten withdrawal
or challenge. A fundamental prerequisite for suspecting NCGS
is to rule out all the established gluten/wheat disorders, compris-
ing coeliac disease (CD), gluten ataxia, dermatitis herpetiformis
and wheat allergy. The major issue not addressed by the consen-
sus opinion was that gluten is only one protein contained within
wheat. Other proteins, such as amylase-trypsin inhibitors
(ATIs),30 are strong activators of innate immune responses in
monocytes, macrophages and dendritic cells. Furthermore,
wheat germ agglutinin, which has epithelial-damaging and
immune effects at very low doses at least in vitro, might also
contribute to both intestinal and extraintestinal manifestations
of NCGS.31
Consequently, a further development of this research ﬁeld led
to suggestions of a broader term, non-coeliac wheat sensitivity
(NCWS). The problems with this term are twofold. First, rye
and barley may be inappropriately excluded. Second, the term
will refer to any wheat component that might be causally
related to induction of symptoms and, therefore, will also
include fructans (FODMAPs). It will then have a very non-
speciﬁc connotation in IBS. A more correct term would then be
non-coeliac wheat protein sensitivity (NCWPS) since this does
not attribute effects to gluten without evidence of such speciﬁ-
city, eliminates the issue of fructan-induced symptoms and
avoids the unknown contribution of rye and barley proteins to
the symptoms. Both NCGS, the currently accepted term, and
NCWPS will be used subsequently in this paper.
Evidence for involvement of sensitivity to wheat proteins
in IBS
Due to the lack of biomarkers, the diagnosis of NCGS still chal-
lenges clinicians as it remains based only on clinical criteria.32 33
In addition, one of the major diagnostic criteria for NCGS,
which is the improvement of symptoms after wheat protein/
gluten exclusion, might be inﬂuenced by a placebo effect experi-
enced by patients after food elimination from their usual diet.34
This is compounded by a huge media drive, via publications,
printed media, television and the internet supported strongly by
celebrity endorsement where a gluten-free diet (GFD) has been
embraced not only as a solution to many symptoms but also
with the erroneous belief that it is healthy not to eat gluten and,
even more, that GFD helps to lose weight. As a result, a high
proportion of US population, for example, switched to GFD
with a marked increase of the global sale of gluten-free foods.35
Because of these facts, it has been hypothesised that NCGS
might be a false problem created by media rather than an emer-
ging clinical entity.36 However, recent studies have provided
strong signals that wheat protein/gluten may speciﬁcally induce
GI and extraintestinal, including psychological, symptoms in at
least some patients with NCGS.37–39
Although epidemiological data are still scanty and approxi-
mate, NCGS may be at least as common as CD (ie, occurring in
≥1% of the general population).40 Similarly to IBS, NCGS
affects more young (third decade of life) women (F:M ratio
>3:1), while, in contrast to IBS, NCGS is diagnosed more com-
monly in tertiary than primary care centres. According to the
National Health and Nutrition Examination Survey, a primary
care programme, NCGS was found in 0.6% over 7762 sub-
jects,41 whereas at the Celiac Disease Center (University of
Maryland) 6% over 5896 subjects were identiﬁed as NCGS.42
In an Italian multicentre prospective survey carried out on 38
referral paediatric and adult centres for the diagnosis of gluten-
related disorders, NCGS and CD were respectively diagnosed in
391 (3.2%) and 340 (2.8%) over 12 255 patients consecutively
studied in a 1-year period.40 Such data have to be viewed,
however, in the light of the failure to actually prove speciﬁc sen-
sitivity to gluten/wheat proteins in double-blind placebo-
controlled (DBPC) cross-over studies in most patients fulﬁlling
the criteria for NCGS.39 43
Although still a matter of debate, several factors have been
postulated to play a role in NCGS pathogenesis. First, NCGS
may be an immune-mediated disorder evoked by innate immun-
ity, as highlighted by the increased expression of toll-like-
receptors (TLRs), mainly TLR2, in the intestinal mucosa.44
More recently, however, the evidence of an increased level of
interferon-γ in small intestinal biopsies of patients with NCGS
after a short (3-day) gluten challenge lends support to a possible
role exerted by adaptive immunity in this syndrome.45 In line
with the latter ﬁndings, the detection of antigliadin antibodies
in >50% of patients with NCGS provides further support to
adaptive immunity in NCGS pathogenesis.46 Second, discordant
data exist on epithelial barrier dysfunction. Initial studies
showed a reduced intestinal permeability in NCGS, thus sug-
gesting an increased intestinal barrier function. This ﬁnding has
been also supported by a signiﬁcantly higher expression of
claudin-4 mRNA, a marker of reduced permeability, in duodenal
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biopsies of patients with NCGS.44 However, more recently,
some evidence for increased intestinal permeability in a sub-
group of patients with IBS-D carrying the human leucocyte
antigen (HLA)-DQ2+/DQ8+ was reported when consuming a
gluten-containing diet compared with a GFD.47 Further studies
are needed. Third, changes of gut microbiota, as detected in
CD,48 might also occur in patients with NCGS. Finally, a
further aspect potentially linking NCGS with IBS is that
HLA-DQ8 transgenic mice sensitised by gliadin displayed an
increased secretion of acetylcholine from the myenteric plexus,
enhancing muscle contractility and epithelial hypersecretion.
Gluten withdrawal reversed both abnormalities.49
Evidence from double-blind placebo-controlled trials
Consistent evidence indicates the existence of an overlap
between IBS and gluten-related disorders. In fact, about 5% of
patients with IBS tests positive for CD and, conversely, CD may
present with typical IBS-like symptoms.50 51 Moreover, IBS-like
symptoms occur in the majority of patients with NCGS,40 while
about one-third of patients with IBS may have NCWPS.37
Although wheat is now established to be linked to IBS, the com-
ponent(s) that actually trigger(s) symptoms remain unknown. In
this line, the only way to conﬁrm the possible role of gluten or
wheat as causative factors of NCGS/NCWPS is a DBPC strat-
egy.27 This is an expensive and time-consuming procedure and,
therefore, it is not yet of routine use being conﬁned to research
setting.37–39 43 52 53 So far, few DBPC trials have been per-
formed. Their design and results are shown in table 1. The ﬁnd-
ings are discordant with a variation from approximately 30% of
920 patients with IBS in a routine clinical setting being sensitive
to wheat protein, of whom the majority has NCWPS associated
with multiple food hypersensitivity,37 to greater symptoms
induction overall with gluten or wheat protein,38 39 53 to
gluten-speciﬁc responses for current feelings of depression but
not for abdominal symptoms.38 53
Reasons for apparent heterogeneity of results require dissec-
tion. First, subject selection might be a factor. For example, con-
tamination of the cohort with CD can unduly skew results. This
is why the exclusion of CD by combined histological and sero-
logical assessment while consuming adequate gluten is so
important. In this respect, a critical point is to decide whether
patients carrying HLA-DQ2/DQ8 and showing increased IEL
density should be excluded from DBPC. Since about 40% of
patients with NCGS is HLA-DQ2/DQ8+ and shows an
increased IEL density, their exclusion would represent a pre-
selection bias. In addition, 30–90% with positive responses to
wheat protein/gluten has elevated IEL density in several
studies.54 In the study in which 30% of patients with IBS
showed sensitivity to wheat, there was a high incidence of
eosinophilic inﬁltration of the mucosa and epithelium, features
not described in the other reports, suggesting a different cohort
being investigated.37 Second, nocebo responses can be a
problem in re-challenge arms as evident in most, but not all,
cross-over studies reported above. In the Australian study, 3 of
37 patients had gluten-speciﬁc induction of symptoms, but none
of those three had such speciﬁcity of responses when a further
DBPC challenge was instituted.43 The Italian study had 3 of 61
patients who demonstrated unequivocal speciﬁcity of
gluten-induction of symptoms.39 It would be interesting to see
if this is reproducible on a further DBPC challenge. Third, the
active product that was used for the challenge differed from
carbohydrate-depleted wheat protein43 53 to puriﬁed gluten39 to
whole wheat ﬂour,37 52 in its dose from low39 43 to
high,37 38 39 52 and in its form of presentation from capsule37 39
to food.38 43 52 Finally, other design features including method
of assessing the end-points and sample size differed.
Based on these ﬁndings, it is reasonable to speculate that
gluten and/or other wheat proteins (such as ATIs)30 can generate
intestinal and extraintestinal manifestations in a subgroup of
patients with IBS. This contention is supported by mechanistic
studies demonstrating epithelial injury and innate and possibly
adaptive immune activation in response to wheat proteins.
However, gluten and wheat are not the only dietary proteins
involved in IBS. Proteins derived from milk, yeast and soy
maybe involved in some,17 37 and IgE-mediated food allergy
and nickel allergy have been reported in a signiﬁcant proportion
of patients with IBS and NCGS/NCWPS.37 40
THE ROLE OF FODMAPS IN IBS
The development of the FODMAP story
Over many years, there have been multiple observations
that ingestion of certain short-chain carbohydrates—lactose,
fructose and sorbitol, and fructo-oligosaccharides and galacto-
oligosaccharides—was able to induce IBS-like symptoms, and
that their restriction in the diet was associated with apparent
improvement in symptoms in some patients with IBS (as
reviewed in detail22). These carbohydrates have several key fea-
tures in common. They are small molecules, containing only
1–10 sugars, and hence are possible osmotically active sub-
stances in the lumen of the intestine. They are slowly absorbed
in the small intestine if monosaccharides are not absorbed at all
if they contain more than one sugar due to lack of suitable
hydrolases. Hence, they are present in the small intestinal lumen
for a prolonged time and do increase the intestinal luminal
water content. Their malabsorption leads to their exposure to
intestinal bacteria, which rapidly ferment them to release short-
chain fatty acids and gases (hydrogen, carbon dioxide and, in
some people, methane). Their effects on symptoms and gas pro-
duction are also additive.
Two hypotheses were proposed: (1) the luminal distension
evoked by FODMAPs was related to symptom generation; (2) in
patients with IBS and its associated visceral hypersensitivity,
reducing the intake of all those short-chain carbohydrates
would optimally improve the symptom burden. This was differ-
ent to previous dietary strategies in that only one or two species
of those carbohydrates—for example, lactose in lactose malab-
sorbers, fructose alone or in combination with sorbitol or fruc-
tans in fructose malabsorbers—were restricted.
Structure and implementation of the low FODMAP diet
A dietary approach was designed to reduce the intake of all
FODMAP groups, by ﬁnding in each food group low-FODMAP
alternatives. Other adjuncts to reducing FODMAP intake, such
as the use of lactase in food or orally to reduce lactose content
of relevant foods, and the use of co-ingestion of glucose with
food containing an excess of free fructose, were also proposed
in patients with IBS.22 Knowledge of the FODMAP content of
foods was patchy and limited, and an ongoing programme of
detailed food analyses has corrected aberrant assumptions and
ﬁlled in many gaps.55–57 Such information has been made
readily available by an application (the Monash University Low
FODMAP Diet App) that is updated regularly.
The diet has been implemented by education via a dietitian
trained in the principles of the diet. The dietitian would tailor
the dietary advice to the eating patterns of the individual,
ensure nutritional adequacy and provide written information
and where to ﬁnd accurate digital information. After 4–6 weeks,
no or minimal response in an adherent patient should then lead
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Table 1 Summary of double-blind placebo-controlled trials in non-coeliac patients with IBS symptoms and suspected gluten/wheat sensitivity
Study design Inclusion criteria
Mode of administration of
gluten/wheat (g/day) Placebo Duration of the trial Results Reference
Cross-over DBPC Non-coeliac patients (n=6) with
chronic diarrhoea, abdominal pain,
bloating, rumbling, malaise,
nausea, weight loss, recurrent
mouth ulcerations.
Improvement after GFD and
worsening on gluten challenge.
Mean average GFD at DBPC time:
46 months
Tomato soup supplemented with
sachets made up of gluten-
containing flour (20 g/day)
Tomato soup
supplemented with
gluten-free flour sachets
4 weeks with administration of
sachets randomly through each day
for the first 3 days of weeks 2 and 4
Significant worsening of overall intestinal
symptoms for each patient in the week of
gluten-containing flour administration vs the
control week (p=0.0025)
Cooper et al52
Randomised DBPC Patients with IBS (n=34) with
symptoms fulfilling Rome III
criteria.
Improvement of symptoms after
GFD for at least 6 weeks before
DBPC
Gluten-free bread/muffin
supplemented with
carbohydrate-depleted wheat
protein (16 g/day)
Gluten-free bread/
muffin
6 weeks with daily administration of
bread/muffin with or without wheat
protein randomly
Significant worsening of overall symptoms
(abdominal pain, bloating, satisfaction in stool
consistency, tiredness) in patients with wheat
protein ingestion vs those without wheat protein
ingestion (p=0.047)
Biesiekierski et al53
Cross-over,
randomised DBPC
Patients with IBS (n=276) with
symptoms fulfilling Rome II
criteria.
Improvement of symptoms after
GFD
Wheat flour-containing capsules
(13 g/day)
Xylose-containing
capsules
5 weeks with one type of capsules for
2 weeks, washout in the 3rd week
and the other type of capsules in the
4th and 5th week
Significant worsening of overall intestinal
symptoms in the weeks of wheat administration
vs the weeks without wheat ingestion
(p<0.0001)
Carroccio et al37
Cross-over
randomised DBPC
Patients with suspected NCGS who
fulfilled Rome III criteria for IBS
(n=37)
Improvement of symptoms after
GFD for at least 6 weeks before
DBPC
Food with high (16 g/day) or low
content (2 g/day) of
carbohydrate-depleted wheat
protein
Gluten-free food with
whey protein (16 g/day)
2-week-run-in period with a
low-FODMAPs diet, then 1 week with
high or low-gluten diet or placebo,
followed by a 2-week washout before
crossing over to the next diet
Significant improvement of overall intestinal
symptoms during reduced FODMAP diet
(p<0.0001) and significant but similar worsening
on a diet with wheat protein or placebo—3
patients with wheat protein-specific response
Biesiekierski et al43
Cross-over
randomised DBPC
Patients with suspected NCGS who
fulfilled Rome III criteria for IBS
(n=22)—subset of population as
Biesiekierski et al43
Food with high content of
carbohydrate-depleted wheat
protein (16 g/day)
Gluten-free food with
whey protein (16 g/day)
or placebo
3 days with high gluten, whey protein
or placebo diet with ≥3-day washout
before crossing over to the next diet
Significant but similar worsening of abdominal
symptoms in all dietary arms—no patient with
specific wheat protein-mediated response.
Specific increase in current feelings of depression
in wheat protein arm (p=0.011)
Biesiekierski et al;43
Peters et al38
Cross-over
randomised DBPC
Patients with suspected NCGS
(n=61) with intestinal (IBS-like)
and extra-intestinal symptoms
Capsules (4.375 g/day)
containing purified gluten
Rice starch containing
capsules
1 week with one type of capsules,
1 week washout before crossing over
to another week with the other type
of capsules
Significant worsening of overall symptoms after
gluten ingestion vs placebo (p=0.034) (bloating,
p=0.040, abdominal pain, p=0.047, foggy mind,
p=0.019, depression, p=0.020, aphthous
stomatitis, p=0.025)
3 patients with gluten-specific response
Di Sabatino et al39
DBPC, double-blind, placebo-controlled; FODMAPs, fermentable oligo-di-monosaccharides and polyols; GFD, gluten-free diet; NCGS, non-coeliac gluten sensitivity; NCWS, non-coeliac wheat sensitivity;
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to the abandonment of FODMAP restriction. If there has been a
good response, consideration is then given to reducing the level
of restriction by graded reintroduction of previously restricted
foods with a focus on speciﬁc FODMAP groups. The patient is
encouraged in the long term to restrict only to the level that is
needed for symptomatic comfort.
Evidence to support the low FODMAP approach
It is timely to critically review whether the FODMAP concept
and the use of a low FODMAP diet in patients with IBS are sup-
ported by evidence.
Mechanisms of action
Water output from the small bowel varied by a mean of 20%
between diets of moderate and low intake in ileostomates,58 and
the volume of water in the small intestinal lumen as shown by
MRI was markedly increased following the ingestion of manni-
tol, fructose or fructans compared with that following
glucose.59 60 Furthermore, the luminal distension induced by
fructose was independent of whether any fructose reached the
large bowel (as shown by breath hydrogen production).60 61
Diets differing in FODMAP content also lead to marked differ-
ences in breath hydrogen production.62 In addition in methane
producers, high FODMAP intake favoured hydrogen production
while low FODMAP intake preferentially led to the production
of methane, which takes up one-ﬁfth of the volume per hydro-
gen atom generated than does hydrogen gas.62 Thus, there is
close correlation between mechanoreceptor stimulation via
small and large intestinal luminal distension and symptom
genesis. Importantly, the degree of luminal distension is unlikely
to differ overall between patients with IBS and healthy controls
since small intestinal distension occurs similarly in both59 and
breath hydrogen production does not differ when fed diets high
or low in FODMAPs.61 62 The difference in symptom gener-
ation relates more to the presence of visceral hypersensitivity as
shown with regard to symptom generation with lactose
malabsorption.63
Unanswered questions include the mechanism by which
FODMAP intake increases gastro-oesophageal reﬂux64 or
induces tiredness.62 The role of chemoreceptor stimulation via
taste receptors or short-chain fatty acid receptors with subse-
quent hormonal changes warrants further exploration. Likewise,
the relationship of the efﬁcacy of the diet with speciﬁc altera-
tions in the microbiome, immune activation, speciﬁc patterns of
dysmotility and the role of changes of gut microbiota when
FODMAP intake is reduced65 in ongoing efﬁcacy have yet to be
explored.
Heterogeneity of physiological effects across FODMAPs
The principle that all FODMAPs have similar physiological
effects and therefore should be considered together is true only
to a limited extent. While all are capable of exerting an osmotic
effect, this will vary according to the molecular weight and the
rapidity of absorption. Thus, fructose and polyols have a greater
osmotic effect per molecule than fructans and
galacto-oligosaccharides, but the number of molecules in the
lumen will fall more distally with fructose and polyols asso-
ciated with their slow absorption as opposed to no absorption
for oligosaccharides. Nevertheless, imaging does show greater
small intestinal distension with fructose and mannitol or sorb-
itol.59 60 Conversely, oligosaccharides will have greater fermen-
tative effects as they are not absorbed as opposed to absorption
of fructose and polyols across the small intestinal wall, which is
likely to vary according to the dose and speed of intestinal
transit, and, for fructose, the luminal glucose content (glucose
facilitates fructose absorption22) and individual absorptive cap-
acity via fructose-speciﬁc transporters. While all FODMAPs are
readily fermented, the relative speeds of fermentation of indi-
vidual FODMAP groups have not been speciﬁcally studied. Each
FODMAP group may have different effects on the structure and
function of microbiota, but this has not been systematically
assessed. In clinical practice, patients report different sensitiv-
ities to FODMAP groups, but such observations have not been
formally studied.
Efﬁcacy of the low FODMAP diet
Seven studies with a variety of designs examining the efﬁcacy of
the low FODMAP diet have been published, and these are out-
lined in table 2.62 66–72 The studies uniformly show efﬁcacy in
around 70% of patients with IBS of any bowel habit type. The
limitations of the evidence presented above include the choice
of placebo (such as habitual diet), the short-term nature of the
studies (3 days to 6 weeks), the lack of blinding in many and
questions about the success of blinding in others.73 74 Such
issues are endemic in dietary intervention studies often without
ready solutions as reviewed by Yao et al.75 However, the consist-
ency of ﬁndings is somewhat reassuring, and durability of the
beneﬁts has been supported by an observational study with a
median duration over 12 months.72
Implementation of the low FODMAP diet
The low FODMAP diet restricts all FODMAP groups in
its induction phase, followed by a step-down in restriction after
4–6 weeks if efﬁcacious, but each aspect of this plan has not
been subject to speciﬁc study. First, the need to restrict across all
FODMAP groups should theoretically be associated with the
highest chance of response, but this has not been tested. In
observational studies, poorly deﬁned diets that restricted fruc-
tose±sorbitol claimed beneﬁts in 40–81% of patients with IBS
or functional bloating.76–78 Similarly, a diet that restricted fruc-
tose and fructans in 62 patients with IBS and fructose malab-
sorption reported beneﬁt in 74%; step-up to other FODMAPs
was only used if response was poor.79 Second, while controlled
trials have shown that maximal response in symptom reduction
occurs within 7 days when all food is provided and a high
degree of adherence is achieved, there is no evidence-base
behind a 4–6 week induction. This duration was proposed give
the patient time to learn the diet and to ensure persistence of
the symptomatic improvement. It also offers a practical time-
frame for review.
Adherence and degree of difﬁculty in following the diet
Adherence was high where all food was provided on the basis of
dietary diaries and breath hydrogen testing.67 However, where
the diet is taught in a clinical setting, the ease to which patients
can apply the diet and the consequent adherence are important
issues. In a prospective evaluation of 90 patients with IBS in
New Zealand, in which the diet was taught by a dietitian via
one or two consultations, 61% of participants stated that the
diet was easy to follow and 44% were able to incorporate the
diet easily into their life.72 Adherence rates were also high, pos-
sibly because non-adherence was associated with symptom
induction.
Risks of a diet low in FODMAPs
Broad dietary change is associated with several risks that might
include the following. First, nutritional adequacy of the low
FODMAP diet has been evaluated in one study, where dietary
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calcium intake was compromised in some patients, presumably
those who restricted lactose. The low FODMAP diet can be
associated with reduction of ﬁbre intake unless action is taken to
seek non-wheat sources of ﬁbre, as is instructed by dietitians
delivering the diet. The nutritional adequacy of the low
FODMAP diet needs to be assessed in a larger population, par-
ticularly in those who are self-taught. Second, the psychosocial
risks of imposing dietary change cannot be underplayed. These
range from difﬁculties in socialisation and eating away from
home through to the precipitation of eating disorders such as
orthorexia nervosa.80 Third, the physiological effects of redu-
cing FODMAP intake beyond those targeted to improve symp-
toms may have other implications. The major effect
documented to date is alteration by varying FODMAP intake of
gut microbiota, such as changing total bacteria abundance and
altering the relative abundance of Biﬁdobacteria.69 Diets differ-
ing in their FODMAP content were also associated with
changes in the relative abundance of strongly butyrate-
producing Clostridal groups or the mucus-associated bacterium
Akkermansia muciniphila, both of which are positively asso-
ciated with health.65 Interestingly, the changes in these bacteria
comprised increased relative abundance in association with
greater FODMAP intake than with the low FODMAP diet arm
per se in comparison to the habitual diet. The health
implications of such changes are not known but raise concerns
about strict restriction of FODMAPs in the long term.
DIETARY THERAPY IN IBS AND PERCEIVED WHEAT
SENSITIVITY
Patients appear to be increasingly recognising an association of
induction of gut symptoms and/or fatigue with the ingestion
of wheat products such as bread and pasta. An Australian survey
of 1184 adults identiﬁed that 8% avoid wheat or are gluten-free
to relieve such symptoms.25 Because of the coexistence of fruc-
tans and gluten in wheat,57 the dilemma from a clinical point of
view is which of the two evidence-based dietary approaches—
GFD or low FODMAP diet—does one advise after excluding
coeliac disease. A low FODMAP diet may offer a higher chance
of symptomatic response, but GFD involves attacking a speciﬁc
pathogenic factor if the injurious nature of wheat protein is inte-
gral to the genesis of visceral hypersensitivity or other
gut-related physiological changes. In the absence of a biomarker
of NCWPS, the only available means of identifying speciﬁc sen-
sitivity to wheat protein is a trial of exclusion diet (strict GFD)
and then DBPC re-challenge using puriﬁed wheat protein or
gluten with symptoms as the read-out, as discussed earlier.
There is no consensus regarding the choice of approach.
Comparisons between the two dietary approaches are shown in
Table 2 Summary of clinical trials evaluating efficacy of the low FODMAP diet in patients with IBS
Study design
Inclusion
criteria Low FODMAP Comparator
Duration of the
trial Results Reference
Single-blind,
randomised
cross-over
Healthy subjects
(n=15) and
patients with
IBS (n=15)
All food provided with
low FODMAP content
(9 g/day)
All food provided with
high FODMAP content
(50 g/day)
2 days of
interventions with
7-day washout
Abdominal symptoms and
lethargy greater with the high
FODMAP diet in IBS (p=0.002).
Only increased flatus production
in health controls
Ong et al62
Non-randomised
comparative
Patients with
IBS (n=72)
Dietitian-taught low
FODMAP diet
Dietitian-taught standard
diet
Assessed by
questionnaire at
follow-up dietetic
appointment
Satisfaction with IBS symptoms
76% with low FODMAP diet vs
54% with standard diet;
composite symptom score 86% vs
49% (p<0.001); improvements in
bloating 82% vs 49% (p=0.002),
abdominal pain 85% vs 61%
(p=0.023); flatulence 87% vs
50% (p=0.001).
Staudacher
et al68
Single-blind
randomised
Patients with
IBS
Dietitian-taught low
FODMAP diet (n=19)
Habitual diet (n=22) 4 weeks Adequate control of symptoms
68% of 19 for low FODMAP diet
vs 23% of 22 with habitual diet
(p=0.005)
Staudacher
et al69
Prospective
observational
Patients with
IBS (n=90)
Dietitian-taught low
FODMAP diet
Nil Mean 15.7 months 72% satisfied with symptom
response via questionnaire; 76%
adherent to the diet
De Roest
et al72
Single-blind,
randomised
cross-over
Patients with
IBS who fulfilled
Rome III criteria
for IBS (n=30).
Healthy controls
(n=8)
All food provided with
low FODMAP content
All food provided with
FODMAP content similar
to estimated content of a
typical Australian diet
3 weeks for each
dietary intervention
with at least 3 weeks
washout between
For the low FODMAP diet
▸ Lower abdominal symptoms
than typical FODMAP diet
(p<0.001)
▸ Improved symptoms compared
with habitual diet during
run-in (p<0.001)
▸ 70% showed clinically
significantly improvement
Halmos
et al67
Consecutive
prospective
observational
Patients with
IBS (Rome III;
n=19)
e-health-delivered low
FODMAP diet
Habitual diet 6 weeks habitual diet
followed by 6 weeks
low FODMAP diet
Improvement in symptoms and
quality of life with low FODMAP
diet
Pederson
et al70
Non-blinded
randomised
placebo-controlled
Patients with
IBS (Rome III)
e-health-delivered low
FODMAP diet (n=42)
Probiotic+habitual diet
(n=41); and habitual
diet alone (n=40)
6 weeks Low FODMAP diet superior to
placebo (p<0.01), but not to
probiotic (p=0.20); probiotic not
superior to placebo (p=0.13)
Pederson
et al71
FODMAPs, fermentable oligo-di-monosaccharides and polyols.
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table 3. The GFD approach might be preferable if the clinic is
geared towards exclusion diet followed by DBPC re-challenge.
Those having a negative response could have a trial with low
FODMAP diet. Alternatively, the re-challenge methodology
might be better applied in those with biomarkers suggesting
relevant pathogenic events occurring in the intestine. Increased
duodenal IEL density (>25/100 enterocytes), raised faecal
eosinophilic cationic protein and tryptase,81 basophil activation
in vitro18 or circulating antibodies to whole gliadin might
enable better targeting of wheat protein challenges.37 A third
alternative is that the low FODMAP diet is applied initially and,
in those with insufﬁcient response, gluten is also removed from
the diet. If an adequate response occurs, then non-wheat-based
FODMAP intake can be cautiously increased in a step-wise
fashion to determine whether that is necessary.
FUTURE PERSPECTIVES
Much of the controversy has been generated by the poor aware-
ness of the potential components of wheat that can induce symp-
toms. Gluten has been assumed to be the culprit because of its
unequivocal key role in the pathogenesis of coeliac disease. In
this way, the use of ‘gluten’ should be restricted to situations
where gluten is the documented inducer of symptoms, ‘wheat
protein’ where that has been the challenged factor, and ‘wheat’
where wheat products, such as bread, are used as the challenging
agent. Likewise, further consideration will be needed in the
terminology of clinical syndromes so that the current confusion
of NCGS, NCWS and NCWPS can be put to rest. The lack of
biomarkers for food protein sensitivity per se or individual
protein sources is a signiﬁcant impediment to progress. There has
been considerable advancement in the application of techniques,
such as confocal endomicrosocopy,17 which holds promise as
gold standards upon which practical biomarkers might be
compared.
For interventional studies, exclusion of CD is critical and
non-gluten-dependent diagnostic tests such as detection of
gluten-reactive T-cells ex vivo82 are needed. Likewise, the design
of such studies may beneﬁt from expert consensus about several
of the details to reduce heterogeneity and to improve the inter-
pretation of outcomes. Long-term outcomes are also needed to
reassure the durability of efﬁcacy with various dietary strategies.
One missing aspect is whether the intestinal responses to the
dietary proteins are actually translated into altered gut physi-
ology such as visceral hypersensitivity or abnormal motility
responses. If that can be proven, then it places even greater
importance of deﬁning methods of detecting such sensitivities
accurately so that the underlying condition can potentially be
cured rather than just symptomatically treated.
CONCLUSIONS
There has been considerable progress in the understanding of
how dietary change might inﬂuence patient outcomes in IBS.
Table 3 Comparison of gluten-free and low-FODMAP diets in patients with IBS with apparent wheat intolerance
Gluten-free diet Low FODMAP diet
Putative pathogenic
mechanisms targeted
▸ Epithelial injury, alteration of intestinal permeability
▸ Stimulation of innate immune mechanisms
Mechanoreceptor stimulation via luminal distension in small and large intestine
Likelihood of efficacy 24% of 920 patients with IBS36 Efficacy in 68–76%22
Time for response Not reported Within 7 days65
Predictors of response ▸ Increase intraepithelial density in duodenum53
▸ Positive double-blind placebo-controlled re-challenge or
confocal laser endomicrosopic lesions in response to
exposure 17
▸ Latent coeliac disease
Nil reported
Durability of response Durable over 1 year (n=13) 17 72% (n=90) satisfied with mean follow-up 15.7 months72
Ease of introduction ▸ Large amount of high-quality literature available on the
GFD
▸ Dietitians trained in GFD widely in some but not other
countries
▸ No information regarding patients’ perspective
▸ High quality information readily available
▸ Paucity of dietitians trained in this diet in many countries
▸ 61% patients find it easy to follow, 44% easily incorporated into lifestyle in
prospective study (n=90)72
Adherence Not reported in this patient group Adherence 76% in prospective (n=90) observational study72
Advantages ▸ Diet directed to underlying pathogenic mechanism
▸ Widely understood and packaged/processed foods available
in many countries
▸ Restriction only in one food group
▸ High chance of response
▸ In the long term, need only reduce the level of FODMAP intake sufficiently
to achieve symptomatic benefit. Alternatives available across all four food
groups
Disadvantages ▸ Low chance of symptomatic response
▸ Gluten-free packaged/processed food:
– More expensive
– Often high fat, high sugar
– Issues of food texture (breads, pasta, cakes, biscuits)
▸ Exclusion diet=requirement for total abstinence from gluten
▸ Difficult in countries where food labelling inadequate
▸ Symptomatic therapy only
▸ Restrictions across a four food groups
▸ International food database of FODMAP content limited
▸ Limited availability of branded low FODMAP packaged and/or processed
foods
Specific risks: nutritional
adequacy
▸ Restrictions on the intake of many breads and cereals may
lead to deficient intake of folate, thiamine, fibre
▸ Calcium, iron and zinc intake less than population
▸ Many gluten-free foods not nutritionally balanced
▸ If not exchanged for low FODMAP alternatives:
– Restriction of lactose-containing dairy products may lead to deficient
intake of calcium, vitamin D
– Restriction of legumes, grains and cereals may lead to deficient intake of
folate, thiamine, fibre
▸ Natural prebiotic intake reduced65
Specific risks: other ▸ Risks of precipitating an eating disorder
▸ Impaired ability to exclude coeliac disease if diet
commenced prior to investigation
▸ Risks of precipitating an eating disorder
▸ Alteration of gut microbiota when on strict FODMAP restriction67 has
unknown implications for long term
FODMAP, fermentable oligo-di-monosaccharides and polyols; GFD, gluten-free diet.
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The often heated arguments and controversies over the involve-
ment of wheat and its components in inducing symptoms have
led to a now productive and healthy state of enquiry, with
several research groups pursuing an understanding of how pro-
teins and carbohydrates can contribute to IBS symptoms.
Considerable more research is needed, but the learnings are
informing future research into other, non-wheat dietary proteins
and into bioactive chemicals, for which there is growing interest.
The place of diet, whether it be low FODMAP diet, GFD or
other fancy diets, is now established in the therapeutic strategies
that clinicians can offer their patients. While the truth remains
clouded, facts are emerging from the ﬁction.
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